The common interests of the Brain Tumor Research Program are primary malignant brain tumors of adults and children. The scientific goals are to:
Conduct epidemiological and molecular epidemiological studies to investigate etiology and to identify populations at greater and lesser risk for development of malignant brain tumors in adults and children
Determine molecular mechanisms of transformation, altered growth control, and invasion of malignant brain tumors of adults and children
Identify new drugs active against primary brain tumors of adults and children
Determine mechanisms of drug resistance in primary brain tumors, and to institute methods to overcome drug resistance
Develop monoclonal antibodies and recombinant DNA antibody fragments reactive with molecular targets, primary brain tumors, and to develop immunoconjugates for brain tumor treatment
Develop new radiolabeling technology for peptides and monoclonal antibodies and their fragments that will facilitate the investigation of promising radionuclides, including the α-emitter 211Astatine and the beta-emitter 177Lutetium, in targeted radiotherapy clinical trial for brain tumor patients
Develop cell-mediated immunotherapy and dendritic-based vaccine trials for brain tumors
Develop oncolytic poliovirus with no neurovirulence, but retention of oncolytic capacity for gliomas, into a reagent that can be used for therapy of malignant gliomas and neoplastic meningitis from breast cancer
Develop imaging capabilities with Positron Emission Tomography (PET) for improved brain tumor diagnosis, monitoring of therapeutic response, and determination of patient-specific radiation dosimetry in radiolabeled antibody, chemotherapy and small molecular inhibitor clinical trials in brain tumor patients
Design and execute Phase I, Phase II, and Phase III clinical trials in primary and metastatic brain tumors in adults and children, based on laboratory discoveries within the Program, and to execute clinical trials for improvement of quality of life in brain tumor patients
Duke continues to lead the nation in having the largest clinical brain tumor service, seeing between 800 and 900 new brain tumor patients annually.
Marathon runner Tom O’Donnell says he doesn’t run to go fast. He says he has a battle on his hands and he’s got to be in the best shape possible if he’s going to live life to the fullest. More.
Duke Cancer Institute constellates the world-class resources of Duke University, Duke Health and the Duke Comprehensive Cancer Center into a collaborative powerhouse. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.Learn More